Figure 1.

Effects of teneligliptin treatment on HFD‐induced obesity and obesity‐induced metabolic disorders. Teneligliptin was administered in the drinking water (80 mg·kg⁻¹·day⁻¹), for a total of 10 weeks, to male 6‐week‐old C57BL/6N mice also fed a HFD. A and B: Body weight gain (A) and food intake (B) were measured during the administration period. C–F: After 10 weeks of treatment, plasma glucose (C) and triglycerol (D) levels, intraperitoneal WAT weight (E) and hepatic triglycerol accumulation levels (F) were determined. Plasma glucose and triglycerol and hepatic triglycerol levels were determined enzymatically. HFD, high‐fat diet; ND, normal diet; Tene, teneligliptin plus HFD. All the values are means + SE (n = 5–8). * P < 0.05, ** P < 0.01.